Adding an immune drug to standard treatment for new brain lymphoma
Official title: R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial tests whether adding a drug called penpulimab helps people with a lymphoma that starts in the brain.
Read our full plain-language summary
What the trial team says
This is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type). Eligible participants are randomized 1:1 to the experimental arm (R-MA-PD-1: rituximab, methotrexate, cytarabine plus penpulimab) or the control arm (R-MA: rituximab, methotrexate, cytarabine). Induction is administered every 21 days for 6 cycles, followed by risk- and response-adapted consolidation (ASCT or whole-brain radiotherapy) and penpulimab maintenance. The primary objective is to compare the 2-year progression-free survival rate between the two arms.
Key facts
- Registry number
- NCT07764601
- Stage of testing
- Not applicable
- Conditions studied
- Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
Where it is running
This trial lists 5 sites.
-
Jiangsu
- The First People's Hospital of Changzhou (Changzhou)
- The First People's Hospital of Huai'an (Huai'an)
- The First Affiliated Hospital of Nanjing Medical University (Nanjing)
- Wuxi People's Hospital (Wuxi)
- Yixing People's Hospital (Yixing)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.